Abstract:Targeted protein degradation (TPD) has emerged as a prominent and vital strategy for therapeutic intervention of cancers and other diseases. One such approach involves the exploration of proteolysis targeting chimeras (PROTACs) for the selective elimination of disease-causing proteins through the innate ubiquitin-proteasome pathway. Due to the unprecedented achievements of various PROTAC molecules in clinical trials, researchers have moved towards other physiological protein degradation approaches for the targeted degradation of abnormal proteins, including lysosome-targeting chimeras (LYTACs), autophagy-targeting chimeras (AUTACs), autophagosome-tethering compounds (ATTECs), molecular glue degraders, and other derivatives for their precise mode of action. Despite numerous advantages, these molecules face challenges in solubility, permeability, bioavailability, and potential off-target or on-target off-tissue effects. Thus, an urgent need arises to direct the action of these degrader molecules specifically against cancer cells, leaving the proteins of non-cancerous cells intact. Recent advancements in TPD have led to innovative delivery methods that ensure the degraders are delivered in a cell- or tissue-specific manner to achieve cell/tissue-selective degradation of target proteins. Such receptor-specific active delivery or nano-based passive delivery of the PROTACs could be achieved by conjugating them with targeting ligands (antibodies, aptamers, peptides, or small molecule ligands) or nano-based carriers. These techniques help to achieve precise delivery of PROTAC payloads to the target sites. Notably, the successful entry of a Degrader Antibody Conjugate (DAC), ORM-5029, into a phase 1 clinical trial underscores the therapeutic potential of these conjugates, including LYTAC-antibody conjugates (LACs) and aptamer-based targeted protein degraders. Further, using bispecific antibody-based degraders (AbTACs) and delivering the PROTAC pre-fused with E3 ligases provides a solution for cell type-specific protein degradation. Here, we highlighted the current advancements and challenges associated with developing new tumour-specific protein degrader approaches and summarized their potential as single agents or combination therapeutics for cancer.

Targeted Protein Degradation Technology and Nanomedicine: Powerful Allies Against Cancer

Targeted protein degrader development for cancer: advances, challenges, and opportunities

Targeted protein degradation in cancers: Orthodox PROTACs and beyond

Targeted protein degradation: advances in drug discovery and clinical practice

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance

Development of natural product-based targeted protein degraders as anticancer agents

Targeted protein degradation in drug development: Recent advances and future challenges

[Advances of targeted protein degradation technology and its applications in diseases therapy].

Novel approaches to targeted protein degradation technologies in drug discovery

Powering up targeted protein degradation through active and passive tumour-targeting strategies: Current and future scopes

Beyond Canonical PROTAC: Biological Targeted Protein Degradation (Biotpd)

Targeted protein degradation: mechanisms, strategies and application

Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins

Expanding the Horizons of Targeted Protein Degradation: A Non-Small Molecule Perspective

Progress of small molecules for targeted protein degradation: PROTACs and other technologies

Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques

Recent advances in targeted protein degraders as potential therapeutic agents

Natural Product-Inspired Targeted Protein Degraders: Advances and Perspectives

PROTAC targeted protein degraders: the past is prologue

From PROTAC to TPD: Advances and Opportunities in Targeted Protein Degradation